Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 15 March 2007, Vol. 109, No. 6, pp. 2597-2603.
Prepublished online as a Blood First Edition Paper on December 5, 2006; DOI 10.1182/blood-2006-05-020545.

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Tables and Figures
Right arrow All Versions of this Article:
blood-2006-05-020545v1
109/6/2597    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dutton, A.
Right arrow Articles by Murray, P. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dutton, A.
Right arrow Articles by Murray, P. G.
Related Collections
Right arrow Neoplasia
Right arrow Oncogenes and Tumor Suppressors
Right arrow Free Research Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

NEOPLASIA

Bmi-1 is induced by the Epstein-Barr virus oncogene LMP1 and regulates the expression of viral target genes in Hodgkin lymphoma cells

Amanda Dutton1, Ciaran B. Woodman1, Marilyn B. Chukwuma1, James I. K. Last1, Wenbin Wei1, Martina Vockerodt1, Karl R. N. Baumforth1, Joanne R. Flavell1, Martin Rowe1, A. Malcolm R. Taylor1, Lawrence S. Young1, and Paul G. Murray1

1 Cancer Research UK Institute for Cancer Studies, The Medical School, University of Birmingham, Edgbaston, United Kingdom


   Abstract
Top
 Abstract
Introduction
 Materials and methods
 Results
 Discussion
 Authorship
 References
 
Polycomb group (PcG) proteins are chromatin modifiers that are necessary for the maintenance and renewal of embryonic and adult stem cells. However, overexpression of the PcG protein, Bmi-1, causes lymphoma in transgenic mice. We show that Bmi-1 is up-regulated in Hodgkin lymphoma (HL) cells by the Epstein-Barr virus (EBV) oncogene latent membrane protein-1 (LMP1) and that this up-regulation is mediated by NF-{kappa}B signaling. We also show that Bmi-1 is up-regulated by NF-{kappa}B in EBV-negative HL cells. Down-regulation of LMP1 and Bmi-1 decreased the survival of HL cells, suggesting that Bmi-1 may mediate the prosurvival effects of LMP1-induced NF-{kappa}B signaling in HL cells. Transcriptional targets of Bmi-1 were identified after its knockdown in an HL cell line. We show here that Bmi-1 and LMP1 down-regulate the ataxia telangiectasia–mutated (ATM) tumor suppressor and conclude that Bmi-1 contributes to LMP1-induced oncogenesis in HL.


   Introduction
Top
 Abstract
 Introduction
Materials and methods
 Results
 Discussion
 Authorship
 References
 
Classical Hodgkin lymphoma (HL) is derived from germinal center (GC) B cells and is characterized by malignant Hodgkin/Reed-Sternberg (HRS) cells in a background of nonmalignant "reactive" cells.1 The Epstein-Barr virus (EBV) is present in HRS cells in approximately half of all patients with HL, in whom it expresses a restricted set of virus-latent genes; these include the major EBV oncogene latent membrane protein-1 (LMP1).2 By mimicking a constitutively active CD40 receptor, LMP1 activates signaling pathways, such as NF-{kappa}B, which enhance B-cell survival and are essential for EBV-induced transformation.3,4

Polycomb group (PcG) genes are necessary for the maintenance and renewal of embryonic and adult stem cells, embryogenesis, and cell cycle regulation.5,6 Two polycomb repressive complexes, PRC1 and PRC2, are required for the initiation and maintenance of gene silencing, respectively.7–9 Bmi-1/PCGF4 (B lymphoma Mo-MLVinsertion region/polycomb group ring finger 4) is a component of PRC1.10,11 Bmi-1 induces lymphoid proliferation and the development of lymphomas in transgenic mice.12–15 Bmi-1 is highly expressed in high-grade large B-cell lymphomas, mantle cell lymphoma, and nonlymphoid malignancies, such as colorectal cancer and non–small cell lung cancer.16–18 Although Bmi-1 is highly expressed in HRS cells,19–21 its regulation and contribution to the pathogenesis of HL are unknown. We show here that Bmi-1 is a transcriptional target of LMP1, that the expression of Bmi-1 promotes the survival of HL cells, and that Bmi-1 induces transcriptional changes in HL cells that include the down-regulation of the ataxia telangiectasia mutated (ATM) gene.


   Materials and methods
Top
 Abstract
 Introduction
 Materials and methods
Results
 Discussion
 Authorship
 References
 
The work undertaken in the study received ethical approval from the South Birmingham Research Ethics Committee (LREC no.0844).

Cell lines and tissue samples

EBV-negative cell lines from mixed cellularity (MC) HL (KM-H2) and nodular sclerosis (NS) HL (L428)22 were maintained in RPMI 1640 supplemented with 10% fetal calf serum, 2 mM L-glutamine, and 1% penicillin-streptomycin solution (Sigma-Aldrich, Poole, United Kingdom). An EBV-positive cell line from a patient with NS HL (L591) and an EBV-negative clone of this line (L591-SD3) were grown in the same way.23 Paraffin-embedded HL biopsies were obtained from Queen Elizabeth Hospital, (Birmingham, United Kingdom), and their EBV status was determined by immunohistochemical staining for LMP1.24

Transient transfection of HL lines

Transfection of HL-derived cell lines was performed using the nucleofector unit supplied by Amaxa GmbH and described by Schakowski et al.25 In brief, 2 x 106 KM-H2 cells and 4 x 106 other HL cell lines were pelleted at 1500g for 9 minutes. After resuspension in 100 µL freshly prepared nucleofector solution kit T (catalog no. VCA-1002; Amaxa, Cologne, Germany), 2 µg plasmid DNA was added to KM-H2 and 4 µg was added to the other HL cells. Subsequently, KM-H2 cells were pulsed using program T-01, and the other HL cells were pulsed using program U-09; cells were then incubated in culture media and analyzed after 24 and 48 hours.

Reverse transcription–polymerase chain reaction

Total RNA was extracted from cell lines using the StrataPrep Total RNA Microprep Kit (catalog no. 400805; Stratagene, La Jolla, CA), according to the protocol of the manufacturer. cDNA was synthesized using gene-specific primers in a reverse transcription reaction using AMV reverse transcriptase (Roche, Welwyn Garden City, United Kingdom). Gene transcripts were amplified with the following primers: Bmi-1 forward, 5'-GCCTTCTCTGCTATGTCTGAA-3', Bmi-1 reverse, 5'-CTGATGAACACACACCAACTT-3'; LMP1 forward, 5'-ACAATGCCTGTCCGTGCAAA-3', LMP1 reverse, 5'-CTTCAGAAGAGACCTTCTCT-3'; GAPDH forward, 5'-GGTGAAGGTCGGAGTCAACGGA-3', GAPDH reverse, 5'-GAGGGATCTCGCTCCTGGAAGA-3'; HK2 forward, 5'-GGTGGACAGGATACGAGAAAA-3', HK2 reverse, 5'-GGGTCCTCTCTGCCAGCAA-3', ATM forward, 5'-GTGGGTATTCCGACTTTGTT-3', ATM reverse, 5'-GTGGGTATTCCGACTTTGTT-3'.

PCR was performed using "hot start" (Red Hot Taq DNA Polymerase; Abgene, Epsom, United Kingdom), which consisted of an initial 2-minute denaturation at 94°C, followed by 25 cycles, consisting of a denaturing step for 30 seconds at 94°C, an annealing step for 1 minute at 45°C, and an extension for 1 minute at 72°C. For semiquantitative analysis, 15, 20, and 25 PCR cycles were performed. PCR products were visualized on 2% agarose gels.

Western blot analysis

HL cell lines were washed in cold PBS and lysed in 80 µL lysis buffer (20 mM Tris HCl buffer [pH 7.4], 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100). Protein concentrations were determined using the Dc protein assay (Bio-Rad, Hercules, CA), and proteins were transferred to nitrocellulose membranes after their separation by 10% SDS-PAGE. After a 1-hour incubation in blocking solution (5% milk in PBS, 0.01% Tween 20), blots were probed overnight with primary antibody for Bmi-1 (clone 229F6; mouse monoclonal diluted 1/1000; Upstate Laboratories, Syracuse, NY), LMP1 (CS1-4, prepared in house; mouse monoclonal diluted 1/50), HK2 (clone-14, goat polyclonal diluted 1/200; Santa Cruz Biotechnology, Santa Cruz, CA) or actin (clone-2, mouse monoclonal 1/500; Santa Cruz Biotechnology). Fifty micrograms of whole cell lysates separated by 6% SDS-PAGE were immunoblotted with ATM antibody (11G12 mouse monoclonal antibody, 1:500).26 After washing in PBS, the secondary peroxidase-labeled antibody (Dako, Bucks, United Kingdom) was added at 1:1000. Proteins were visualized with the enhanced chemiluminescence (ECL) technique (Amersham, Little Chalfont, Buckinghamshire, United Kingdom).

Inhibition of NF-{kappa}B activity

HL cells were incubated with the NF-{kappa}B inhibitor tosyl-L-lysine chloromethyl ketone hydrochloride (TLCK; Sigma-Aldrich) for 6 hours at a 1:500 dilution (100-mM stock) in growth medium; this proteasome inhibitor prevents the degradation of I{kappa}B-alpha and inhibits the processing of the p105 subunit of NF-{kappa}B. After treatment, cells were centrifuged, washed twice in cold PBS (pH 7.6), and resuspended in RNA extraction buffer or protein lysis buffer. HL cells were also transiently transfected with an expression vector encoding a mutant form of I{kappa}B{kappa}. Because the phosphorylation of this mutant I{kappa}B{kappa} is prevented by the substitution of alanine for serine residues at positions 32 and 36, it has a dominant-negative phenotype that prevents the activation of NF-{kappa}B by sequestering it in the cytoplasm.27 Finally, HL cells were transfected with pSG5 vectors expressing either wild-type LMP1 or a mutant LMP1 (AxAxA 386 stop) that lacks the CTAR1 and CTAR2 domains, each of which is responsible for NF-{kappa}B activation.4

RNA interference

LMP1 expression was knocked down using exogenously supplied oligonucleotides (5'-UUUGCACGGACAGGCAUUG-3' and 3'-AAACGUGCCUGUCCGUAAC-5'), designed and manufactured by Eurogentec (Seraing, Belgium). Before transfection, 30 µL each of the RNA oligonucleotide solutions (50 µM) was combined with 15 µL annealing buffer (final buffer concentration: 100 mM potassium acetate, 30 mM HEPES-KOH [pH 7.4], 2 mM magnesium acetate). These solutions were incubated for 1 minute at 90°C, briefly centrifuged, and incubated for another hour at 37°C. siRNAs (20 µM) were stored at –20°C until transfection. HL cells were diluted with media to a density of 2.5 x 105 cells per 250 µL in 24-well plates. A mixture containing 3 µL RiboJuice (Novagen, Freiburg, Germany) transfection reagent, 47 µL serum-free medium, and siRNA (final concentration, 2 µM) was added to each well. Plates were left overnight at 37°C in 5% CO2; samples were then centrifuged and resuspended in 1 mL culture medium. Bmi-1 expression was knocked down either by nucleofection of HL cell lines with a pSUPER-retro vector expressing a Bmi-1–specific short hairpin (sh) RNA (target sequence gta ttg tcc tat ttg tga t [gift of Maarten van Lohuizen, The Netherlands Cancer Institute, Amsterdam]) or with an exogenous oligonucleotide (5'-CCAGACCACUACUGAAUAU-3'), as described.

Trypan blue cell viability assay

Cell viability after siRNA transfection was assessed in triplicate using the trypan blue reagent (Sigma-Aldrich). Cell suspension (100 µL) was removed from plates and mixed with 100 µL trypan blue reagent for 2 minutes. Viability was determined by direct counting of unstained cells in a hemocytometer.

Immunohistochemistry

Paraffin-embedded tissues were cut at 5 µm onto adhesive-coated slides (Vectabond reagent; Novocastra Laboratories, Newcastle, United Kingdom). After dewaxing of paraffin sections, endogenous peroxidase activity was blocked by incubation of all slides for 10 minutes in 3% hydrogen peroxide in methanol. Antigens were retrieved by incubation overnight in EDTA 1 mM (pH 8.0)/Tween 20 (0.1%) buffer on a hot-plate stirrer at 65°C. Primary antibodies used were Bmi-1 (dilution 1:50; Upstate Laboratories), LMP1 (dilution 1:50; CS1-4),24 and HK2 (dilution 1:50; Santa Cruz Biotechnology). Detection of bound primary antibody was performed using the Envision IHC Select kit (Dako).

Gene expression analysis

For analysis of gene expression after Bmi-1 knockdown, L428 cells were transfected with a pSUPER retro vector expressing Bmi-1–specific shRNA or control vector, as described. Successful knockdown of Bmi-1 was confirmed using RT-PCR and immunoblotting. Knockdown was performed in triplicate, and pooled RNA from each transfection was used to prepare biotinylated RNA hybridized to HG-U133 Plus 2.0 arrays (Affymetrix, Santa Clara, CA). Differentially expressed probe sets were identified using the change algorithm of Affymetrix GCOS with the default settings; only those with "increase" or "decrease" calls were included.


   Results
Top
 Abstract
 Introduction
 Materials and methods
 Results
Discussion
 Authorship
 References
 
LMP1 induces Bmi-1 expression in HL cells

First, we investigated the expression of Bmi-1 in HL cell lines. Figure 1A shows that Bmi-1 was expressed in EBV-positive (L591) and EBV-negative (KMH2, L428) cell lines. We examined the influence of LMP1 on Bmi-1 expression by comparing its expression in EBV-positive and EBV-negative L591 HL cells; loss of EBV was associated with the down-regulation of Bmi-1 expression (Figure 1A). Next we investigated whether LMP1 regulated Bmi-1 expression. The knockdown of LMP1 in L591 cells by specific siRNA led to the down-regulation of Bmi-1 expression (Figure 1B), though the ectopic expression of LMP1 in EBV-negative L428 cells led to its up-regulation (Figure 1C). We concluded that LMP1 can induce the expression of Bmi-1 in HL cells. Ectopic expression of LMP1 in EBV-negative Burkitt lymphoma cell lines did not result in the up-regulation of Bmi-1 expression. However, LMP1 was able to up-regulate the expression of TRAF1, an established LMP1 target in BL cells (Figure S1). These data suggest that among B cells the up-regulation of Bmi-1 by LMP1 might be restricted to certain B-cell lineages.


Figure 1
View larger version (50K):
[in this window]
[in a new window]

  		Figure 1. LMP1 induces Bmi-1 expression in HL cells. (A) Expression of Bmi-1 in EBV-negative HL cell lines L428 and KMH2 and in the EBV-positive (LMP1-positive) L591 HL cell line compared with the EBV-negative variant, L591-SD3. Although Bmi-1 is highly expressed in all parental lines, irrespective of EBV status, loss of the EBV episome from L591 cells resulted in its down-regulation (for all figures, mRNA and protein are shown in upper and lower panels, respectively). (B) Knockdown of LMP1 expression (L591+LMP1 siRNA) down-regulates Bmi-1 expression in EBV-positive L591 cells compared with cells treated with transfection reagent (RiboJuice; Novagen) alone. (C) Ectopic expression of LMP1 in EBV-negative L428 cells up-regulates Bmi-1 expression.

 
LMP1 induction of Bmi-1 is NF-{kappa}B dependent

A number of approaches were used to determine whether NF-{kappa}B mediates the up-regulation of Bmi-1 by LMP1. First, EBV-positive L591 cells were treated with the broad-spectrum NF-{kappa}B inhibitor TLCK; this led to the down-regulation of Bmi-1 (data not shown). Next, L591 cells were transfected with a mutant form of I{kappa}B{kappa}, which inhibits NF-{kappa}B activity.27 This also down-regulated Bmi-1 expression (Figure 2A). Finally, we showed that whereas the ectopic expression of wtLMP1 in EBV-negative L428 cells resulted in Bmi-1 up-regulation, the expression of a mutant LMP1 (AxAxA386stop LMP1), which is incapable of activating NF-{kappa}B, did not (Figure 2B). In keeping with these observations, we were able to demonstrate that loss of the EBV genome, and therefore also LMP1 expression, from L591 cells results in significantly decreased NF-{kappa}B activity (data not shown). We concluded that LMP1 induces Bmi-1 expression by activating the NF-{kappa}B pathway.


Figure 2
View larger version (57K):
[in this window]
[in a new window]

  		Figure 2. LMP1 induction of Bmi-1 is NF-{kappa}B dependent. (A) L591 cells transfected with a plasmid expressing an I{kappa}B{kappa} mutant that inhibits NF-{kappa}B activation. Expression of the I{kappa}B{kappa} mutant resulted in the down-regulation of Bmi-1 expression compared with cells transfected with control vector. (B) L428 cells transfected with control plasmid (empty vector), wild-type (wt) LMP1, or a mutant LMP1 incapable of inducing NF{kappa}B (AxAxA378stop). WtLMP1, but not AxAxA378stopLMP1, induced Bmi-1 expression.

 
Bmi-1 expression in EBV-negative HL cells is also NF-{kappa}B dependent

We found that Bmi-1 expression in primary HRS cells did not vary with EBV status (Figure 3A; Table 1). Therefore, we examined the influence of NF-{kappa}B activity on Bmi-1 expression in EBV-negative HL cells. Bmi-1 was down-regulated in EBV-negative L428 and KMH2 cells after treatment with the NF-{kappa}B inhibitor TLCK (Figure 3B) and after expression of the mutant I{kappa}B{kappa} (Figure 3C). We concluded that Bmi-1 expression in HL cells is regulated by NF-{kappa}B in EBV-positive and EBV-negative HL cells.


Figure 3
View larger version (81K):
[in this window]
[in a new window]

  		Figure 3. Bmi-1 expression in EBV-negative HL cells is also NF-{kappa}B dependent. (A) Immunohistochemistry for Bmi-1 in primary HL. (Top) Typical nuclear staining of HRS cells (arrow) observed in most patients. Only 3 of 60 patients lacked Bmi-1 expression. (Middle) Typical image showing lack of HRS cell expression of Bmi-1 (arrow). (Bottom) Mantle zone (MZ) B cells and centrocytes (CC) were Bmi-1 positive in control tonsil, whereas centroblasts (CBs) were negative. Images were acquired using a Zeiss Photomicroscope II equipped with a Nikon Coolpix990 camera (Nikon, Kingston upon Thames, United Kingdom) and using Corel Paint Shop Pro v.10 software (Maidenhead, United Kingdom). Top two images were acquired with a 60 x/1.40 NA oil-immersion objective lens (Nikon, Kingston upon Thames, United Kingdom); the bottom image, with a 40 x/0.65 NA dry objective lens. (B) Treatment of L428 cells with the NF-{kappa}B inhibitor TLCK resulted in the down-regulation of Bmi-1 expression. Changes in Bmi-1 mRNA (top) and protein (bottom). Similar results were obtained with EBV-negative KMH2 cells (data not shown). (C) KM-H2 cells transfected with a plasmid expressing an I{kappa}B{kappa} mutant that inhibits NF-{kappa}B activation. Expression of the I{kappa}B{kappa} mutant resulted in the down-regulation of Bmi-1 expression compared with cells transfected with control vector.

 


View this table:
[in this window]
[in a new window]

  		Table 1. Bmi-1 expression in primary HL

 
Bmi-1 promotes the survival of HL cells

Given that Bmi-1 is an NF-{kappa}B target and that NF-{kappa}B activation is critical for the survival of HL cells,3 we investigated the contribution of Bmi-1 to HL cell survival. Knockdown of Bmi-1 led to a decrease in the viability of L591 cells and of L428 cells (Figure 4). To confirm the specificity of these effects, we also knocked down Bmi-1 in L591 and L428 cells using an exogenous siRNA directed to a different region of Bmi-1. Compared with cells transfected with a scrambled siRNA, Bmi-1–specific exogenous siRNA reduced the viability of these HL cells (Figure S2). We concluded that in HL cells, Bmi-1 may mediate the prosurvival effects of NF-{kappa}B activation.


Figure 4
View larger version (33K):
[in this window]
[in a new window]

  		Figure 4. Bmi-1 promotes the survival of HL cells. (A) Knockdown of Bmi-1 expression in L591 cells (top) and in L428 cells (bottom). mRNA and protein are shown in the left and right panels, respectively. (B) Knockdown of Bmi-1 led to a marked reduction in the viability of L591 cells (upper) at 24 hours and at 48 hours after transfection compared with control cells (GFP-only vector). Knockdown of Bmi-1 in L428 cells had a significant but less marked effect on cell viability (bottom). Error bars represent the standard error of the mean.

 
Gene expression profiling reveals Bmi-1–regulated genes in HL cells

Gene expression profiling of L428 cells after Bmi-1 knockdown revealed the up-regulation of 771 probe sets and the down-regulation of 383 (including Bmi-1). The complete list of differentially expressed genes is available in Figure S1 (available on the Blood website; see the Supplemental Materials link at the top of the online article). Bmi-1 down-regulated a large number of genes associated with differentiation (Figure S2), including a number of B-cell lineage markers (eg, CD20/MS4A1, BLK, LY9).

A number of genes induced by Bmi-1 are known to be overexpressed in HL.28–30 These include STAT1 and c-MET; both are known transcriptional targets of LMP1.31–33 We confirmed the changes in the expression of several Bmi-1–induced genes, including hexokinase 2 (HK2), Bcl-2/adenovirus E1B 19-kDa interacting protein-3 (BNIP3), and prolyl 4-hydroxylase alpha subunit (P4HA1) (Figure 5); these genes are induced by LMP1. We were also able to show that ectopic expression of LMP1 in L428 cells led to the up-regulation of HK2 (Figure 6A). Although HK2 was overexpressed in primary HRS cells (Figure 6B), this was unrelated to EBV status.


Figure 5
View larger version (59K):
[in this window]
[in a new window]

  		Figure 5. Validation of Bmi-1 target genes identified by microarray analysis. Knockdown of Bmi-1 expression in L428 cells resulted in the down-regulation of HK2, c-MET, BNIP3, and P4HA1 mRNA (left). Changes in the protein levels of HK2, c-MET, and BNIP3 were also demonstrated (right). P4HA1 could not be confirmed at the protein level because of the lack of a suitable antibody.

 


Figure 6
View larger version (71K):
[in this window]
[in a new window]

  		Figure 6. HK2 is a transcriptional target of LMP1 and is overexpressed in HRS cells. (A) Ectopic expression of LMP1 in L428 cells up-regulated the expression of HK2 (mRNA [left] and protein [right]). (B) Immunohistochemistry was used to study the expression of HK2 in primary HL. (Top) Low-level HK2 expression in germinal center (GC) and mantle zone (MZ) B cells of normal tonsil. (Middle, bottom) Strong staining of HK2 in HRS cells (arrow). Images were acquired using a Zeiss Photomicroscope II (Zeiss UK) equipped with a Nikon Coolpix990 camera and using Corel Paint Shop Pro v.10 software. All images were acquired using a 60 x/1.4 NA oil-immersion objective lens.

 
Bmi-1 and LMP1 down-regulate the ATM tumor suppressor in HL cells

Bmi-1–repressed genes included several tumor-suppressor genes epigenetically inactivated in other cancers (Table 2). Given that we have previously shown that one of these genes, ATM, is not expressed at the protein level in HRS cells,26 this gene was selected for further study. We confirmed that ATM gene expression is induced after Bmi-1 knockdown in the L428 and KM-H2 cell lines using either endogenous knockdown (Figure 7A) or exogenously supplied Bmi-1–specific siRNA, which targets a different region of Bmi-1 (Figure S2). This exogenous siRNA also down-regulates the expression of HK2 (data not shown). Next we showed that ATM expression is lower in EBV-positive L591 cells than in EBV-negative L591 cells and that the knockdown of LMP1 in EBV-positive L591 cells up-regulated ATM expression (Figure 7B). Finally, we showed that ATM was also up-regulated after the inhibition of NF-{kappa}B in L428 cells (Figure 7C). We concluded that the down-regulation of ATM by NF-{kappa}B may be mediated by Bmi-1.


View this table:
[in this window]
[in a new window]

  		Table 2. Tumor-suppressor genes epigenetically inactivated in other cancers that were up-regulated by Bmi-1 knockdown in L428 cells

 


Figure 7
View larger version (49K):
[in this window]
[in a new window]

  		Figure 7. Bmi-1 and LMP1 down-regulate expression of the ATM tumor suppressor in HL cells. (A) Knockdown of Bmi-1 expression in L428 cells resulted in the up-regulation of ATM expression. (left) Changes in mRNA. (right) Changes in protein. Knockdown of Bmi-1 in the KM-H2 cell line produced similar effects on ATM expression (data not shown). (B) ATM expression was higher in EBV-negative L591 cells than in EBV-positive L591 cells (left). Knockdown of LMP1 in EBV-positive L591 cells led to the up-regulation of ATM transcription (right). These data show that ATM expression is suppressed by LMP1 in EBV-positive HL cells. (C) Inhibition of NF-{kappa}B in L428 and cells up-regulated ATM expression. Similar effects were also observed in KM-H2 cells (data not shown).

 

   Discussion
Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
Authorship
 References
 
Here we demonstrate that LMP1, the major transforming protein of EBV, can up-regulate the Bmi-1 oncogene and that the up-regulation of Bmi-1 in EBV-positive and EBV-negative HL cells is mediated by NF-{kappa}B. Our observations directly link the overexpression of Bmi-1 in HRS cells to the aberrant NF-{kappa}B signaling characteristic of this tumor. LMP1 may be the major regulator of Bmi-1 expression in EBV-positive HL, whereas other activators of NF-{kappa}B, such as I{kappa}B{alpha} mutations, may be responsible for Bmi-1 up-regulation in EBV-negative disease.34,35 Given that Bmi-1 is overexpressed in a wide range of cancers and that NF-{kappa}B deregulation is strongly associated with oncogenesis,36 a similar relationship between NF-{kappa}B and Bmi-1 should be explored in other cancers.

We found that the viability of HL cells was decreased after Bmi-1 knockdown. Constitutive NF-{kappa}B activation is important for the survival of HL cells3,37,38; therefore, the influence of NF-{kappa}B on HL cell survival may in part be mediated by the ability of NF-{kappa}B to induce Bmi-1 expression. Our findings are consistent with those of a recent report that showed Bmi-1 is required for the short-term survival of cancer cells.39

Microarray analysis after the knockdown of Bmi-1 in L428 cells revealed for the first time the impact of Bmi-1 on the cellular transcriptional program in a transformed cell. Consistent with a recent study in which human embryonic fibroblasts were depleted of PRC1 and PRC2 proteins,40 we observed that Bmi-1 down-regulated a large number of differentiation-related genes; several of these were B-cell lineage markers (CD20/MS4A1, BLK, LY9) previously shown to be down-regulated in HRS cells.41 Thus, Bmi-1 may contribute to the loss of B-cell identity, which is characteristic of HL.

Bmi-1 up-regulated a number of genes, including STAT1 and c-MET, which are overexpressed in HL28–30 and which are also known transcriptional targets of LMP1.31–33 MET is the receptor tyrosine kinase for hepatocyte growth factor that induces ERK and PI3K activation and contributes to oncogenesis in other lymphomas.42 Furthermore, we have shown that other Bmi-1–induced genes were also up-regulated by LMP1. One of these, HK2, is overexpressed in HRS cells and in other cancers, where it is essential for the maintenance of high glycolytic activity.43

Bmi-1 also down-regulated a number of tumor-suppressor genes that are epigenetically silenced in cancer. These include IGSF4, which directly binds the PRC1 and PRC2 complexes40 and which we have recently shown to be methylated in most patients with primary HL (P.G.M., G. Davies, H. Li, Y. Tsang, G. Kapatai, J.R.F., W.W., G. Reynolds, A. Ito, C.B.W., R. F. Ambinder, L.S.Y., and Q. Tao, manuscript submitted). The tumor-suppressor gene ATM, whose biallelic inactivation increases susceptibility to lymphoma, was also down-regulated by Bmi-1 and LMP1. We have shown previously that ATM protein expression is lost in most patients with primary HL.26 We show here that NF-{kappa}B down-regulates ATM. Although mutation and promoter hypermethylation of ATM are responsible for the inactivation of this gene in hematopoietic and solid malignancies, we have been unable to detect any evidence for either of these mechanisms in HL (S. Bose, J. Starczynski, M.B.C., K.R.N.B., W.W., S. Morgan, P. Byrol, R. Grundy, J. R. Mann, Q. Tao, A.M.R.T., P.G.M., and T. Stankovic, manuscript in preparation). Although our data suggest that the up-regulation of Bmi-1 may be responsible for the loss of ATM expression in HRS cells, the mechanism for the transcriptional down-regulation of ATM has yet to be identified; the observation that Bmi-1 has H2A-K119 ubiquitin E3 ligase activity merits further investigation.44

In conclusion, our data suggest that Bmi-1 contributes to LMP1-induced oncogenesis in HL and provide additional insight into how this PcG protein might contribute to oncogenesis at other sites of cancer.


   Authorship
Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 Authorship
References
 
Contribution: A.D. performed the research and wrote the paper. C.B.W. analyzed the data and wrote the paper. M.B.C. performed the immunohistochemistry experiments. J.I.K.L. performed ATM immunoblotting. W.W. analyzed the data. M.V. analyzed the data. K.R.N.B. assisted with microarray work. J.F. generated L591/SD3 cells. M.R. supervised the work with BL cell lines. A.M.R.T. supervised the ATM studies. L.S.Y. designed the research and wrote the paper. P.G.M. designed the research and wrote the paper.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Paul G. Murray, CRUK Institute for Cancer Studies, The Medical School, University of Birmingham, Edgbaston, Birmingham, B15 2TT, United Kingdom; e-mail: p.g.murray{at}bham.ac.uk.


   Acknowledgments
 
We thank the Leukaemia Research Fund, United Kingdom for supporting this project.


   Footnotes
 
Submitted May 15, 2006; accepted October 21, 2006.

Prepublished online as Blood First Edition Paper, December 5, 2006 DOI: 10.1182/blood-2006-05-020545

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.


   References
Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 Authorship
 References
 

  1. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361–1392.[Free Full Text]

  2. Murray PG, Young LS, Rowe M, Crocker J. Immunohistochemical demonstration of the Epstein-Barr virus-encoded latent membrane protein in paraffin sections of Hodgkin's disease. J Pathol 1992; 166:1–5.[CrossRef][Medline] [Order article via Infotrieve]

  3. Bargou RC, Emmerich F, Krappmann K, et al. Constitutive nuclear factor-{kappa}B-RelA activation is required for proliferation and survival of Hodgkin's disease tumour cells. J Clin Invest 1997; 100:2961–2969.[Medline] [Order article via Infotrieve]

  4. Huen DS, Henderson SH, Croom-Carter D, Rowe M. The Epstein-Barr virus latent membrane protein (LMP1) mediates activation of NF-{kappa}B and cell surface phenotype via two effector regions in its carboxyl-terminal cytoplasmic domain. Oncogene 1995; 10:549–560.[Medline] [Order article via Infotrieve]

  5. Simon J. Locking in stable states of gene expression: transcriptional control during Drosophila development. Curr Opin Cell Biol 1995; 7:376–385.[CrossRef][Medline] [Order article via Infotrieve]

  6. Jacobs JJL, Kieboom K, Marino S, De Pinho RA, van Lohuizen M. The oncogene and polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999; 397:164–168.[CrossRef][Medline] [Order article via Infotrieve]

  7. Satijn DP and Otte AP. Polycomb group protein complexes: do different complexes regulate distinct target genes? Biochem. Biophys. Acta 1999; 1447:1–16.[Medline] [Order article via Infotrieve]

  8. Swalt RGAB, van der Vlag J, Gunster MJ, et al. Characterisation of interactions between the mammalian polycomb-group proteins EZH21/EZH2 and EED suggests the existence of different mammalian polycomb-group protein complexes. Mol Cell Biol 1998; 18:3586–3595.[Abstract/Free Full Text]

  9. Satijn DP, Hamer KM, den Blaauwen J, Otte AP. The polycomb group protein EED interacts with YY1, and both proteins induce neural tissue in Xenopus embryos. Mol Cell Biol 2001; 21:1360–1369.[Abstract/Free Full Text]

  10. Gunster MJ, Satijn DP, Hamer KM, et al. Identification and characterisation of interactions between the vertebrate polycomb group protein BMI1 and human homologs of polyhomeotic. Mol Cell Biol 1997; 17:2326–2335.[Abstract]

  11. Shao Z, Raible F, Mollaaghababa R, et al. Stabilisation of chromatin structure by PRC1, a polycomb complex. Cell 1999; 98:37–46.[CrossRef][Medline] [Order article via Infotrieve]

  12. Alkema MJ, Jacobs H, van Lohuizen M, Berns A. Perturbations of B and T cell development and predisposition to lymphomagenesis in EuBMI1 transgenic mice require the BMI-1 RING finger. Oncogene 1997; 15:899–910.[CrossRef][Medline] [Order article via Infotrieve]

  13. van Lohuizen M, Verbeek S, Scheijen B, Wientjen E, van der Gulden H, Berns A. Identification of cooperating oncogenes in Eu-myc transgenic mice by provirus tagging. Cell 1991; 65:737–752.[CrossRef][Medline] [Order article via Infotrieve]

  14. Haupt Y, Alexander WS, Barri G, Klinken SP, Adams JM. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in Eu-myc transgenic mice. Cell 1991; 65:753–763.[CrossRef][Medline] [Order article via Infotrieve]

  15. Haupt Y, Bath ML, Harris AW, Adams JM. Bmi-1 transgene induces lymphomas and collaborates with myc in tumorigenesis. Oncogene 1993; 8:3161–3164.[Medline] [Order article via Infotrieve]

  16. Bea S, Tort F, Pinyol M, et al. BMI-1 gene amplification and overexpression in haematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 2001; 61:2409–2412.[Abstract/Free Full Text]

  17. Kim JH, Yoon SY, Kim CN, et al. The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett 2004; 203:217–224.[CrossRef][Medline] [Order article via Infotrieve]

  18. Vonlanthen S, Heighway J, Altermatt HJ, et al. The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer 2001; 84:1372–1376.[CrossRef][Medline] [Order article via Infotrieve]

  19. Raaphorst FM, van Kemenade FJ, Blokzijl T, et al. Polycomb-group genes in Reed-Sternberg cells of Hodgkin's disease. Am J Pathol 2000; 157:709–715.[Abstract/Free Full Text]

  20. Dukers DF, van Galen JC, Giroth C, et al. Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma derived cell lines. Am J Pathol 2004; 164:873–881.[Abstract/Free Full Text]

  21. Sanchez-Beato M, Sanchez E, Garcia JF, et al. Abnormal PcG protein expression in Hodgkin's lymphoma: relation with E2F6 and NF-{kappa}B transcription factors. J Pathol 2004; 204:528–537.[CrossRef][Medline] [Order article via Infotrieve]

  22. Schaadt M, Diehl V, Stein H, Fonatsch C, Kirchner HH. Two neoplastic cell lines with unique features derived from Hodgkin's disease. Int J Cancer 1980; 26:723–731.[Medline] [Order article via Infotrieve]

  23. Baumforth KRN, Flavell JR, Reynolds GM, et al. Induction of autotaxin by the Epstein-Barr virus promotes the growth and survival of Hodgkin lymphoma cells. Blood 2005; 15:2138–2146.

  24. Murray PG, Swinnen LJ, Constandinou CM, et al. BCL-2 but not its Epstein-Barr virus-encoded homologue, BHRF1, is commonly expressed in posttransplantation lymphoproliferative disorders. Blood 15, 1996; 87:706–711.[Abstract/Free Full Text]

  25. Schakowski F, Buttgereit P, Mazur M, et al. Novel non-viral method for transfection of primary leukemia cells and cell lines. Genet Vaccines Ther 12, 2004; 2:1–11.[CrossRef][Medline] [Order article via Infotrieve]

  26. Starczynski J, Simmons W, Flavell J, et al. Variations in ATM protein expression during normal lymphoid differentiation and among B-cell-derived neoplasias. Am J Pathol 2003; 163:423–432.[Abstract/Free Full Text]

  27. Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U. Control of I{kappa}B{alpha} proteolysis by site-specific, signal-induced phosphorylation. Science 1995; 267:1485–1488.[Abstract/Free Full Text]

  28. Cochet O, Frelin C, Peyron JF, Imbert V. Constitutive activation of STAT proteins in the HDLM-2 and L540 Hodgkin lymphoma-derived cell lines supports cell survival. Cell Signal 2006; 18:449–455.[CrossRef][Medline] [Order article via Infotrieve]

  29. Teofili L, Di Febo AL, Pierconti F, et al. Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease. Blood 2001; 15:1063–1069.

  30. Garcia JF, Camacho FI, Morente M, et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood 2003; 15:681–689.

  31. Zhang L, Hong K, Zhang J, et al. Multiple signal transducers and activators of transcription are induced by EBV LMP-1. Virology 2004; 323:141–152.[CrossRef][Medline] [Order article via Infotrieve]

  32. Horikawa T, Sheen TS, Takeshita H, Sato H, Furukawa M, Yoshizaki T. Induction of c-Met proto-oncogene by Epstein-Barr virus latent membrane protein-1 and the correlation with cervical lymph node metastasis of nasopharyngeal carcinoma. Am J Pathol 2001; 159:27–33.[Abstract/Free Full Text]

  33. Najjar I, Baran-Marszak F, Le Clorennec C, et al. Latent membrane protein 1 regulates STAT1 through NF-{kappa}B-dependent interferon secretion in Epstein-Barr virus-immortalized B cells. J Virol 2005; 79:4936–4943.[Abstract/Free Full Text]

  34. Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B, Scheidereit C. Molecular mechanisms of constitutive NF-{kappa}B/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 1999; 18:943–953.[CrossRef][Medline] [Order article via Infotrieve]

  35. Jungnickel B, Staratschek-Jox A, Brauninger A, et al. Clonal deleterious mutations in the I{kappa}B{kappa} gene in the malignant cells in Hodgkin's lymphoma. J Exp Med 2000; 191:395–402.[Abstract/Free Full Text]

  36. Rayet B and Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999; 18:6938–6947.[CrossRef][Medline] [Order article via Infotrieve]

  37. Hinz M, Lemke P, Anagnostopoulos I, et al. Nuclear factor {kappa}B-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med 2002; 196:605–617.[Abstract/Free Full Text]

  38. Bargou RC, Leng C, Krappmann D, et al. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1996; 87:4340–4347.[Abstract/Free Full Text]

  39. Liu L, Andrews LG, Tollefsbol TO. Loss of the human polycomb group protein BMI1 promotes cancer-specific cell death. Oncogene 2006; 25:4370–4375.[CrossRef][Medline] [Order article via Infotrieve]

  40. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K. Genome-wide mapping of polycomb target genes unravels their roles in cell fate transitions. Genes Dev 2006; 20:1123–1136.[Abstract/Free Full Text]

  41. Schwering I, Brauninger A, Klein U, et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2003; 101:1505–1512.[Abstract/Free Full Text]

  42. Tjin Ep, Groen RW, Vogelzang I, et al. Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Blood 2006; 107:760–768.[Abstract/Free Full Text]

  43. Pedersen PL, Mathupala S, Rempel A, Geschwind JF, Ko YH. Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim Biophys Acta 2002; 10:14–20.

  44. Cao R, Tsukada Y, Zhang Y. Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. Mol Cell 2005; 22:845–54.


Add to CiteULike CiteULike   Add to Connotea Connotea